<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147951">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01174355</url>
  </required_header>
  <id_info>
    <org_study_id>ND0801/001</org_study_id>
    <nct_id>NCT01174355</nct_id>
  </id_info>
  <brief_title>A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)</brief_title>
  <official_title>A Multicenter, Open Label, Escalating Dose Study to Assess the Tolerability and the Safety and to Explore the Efficacy and the Pharmacokinetics of ND0801 in Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroDerm Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuroDerm Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, open label, escalating dose study to assess the tolerability and the safety
      and to explore the efficacy and the pharmacokinetics of ND0801 in adult patients with
      attention deficit/hyperactivity disorder (ADHD).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety &amp; Tolerability Evaluation</measure>
    <time_frame>1 week</time_frame>
    <description>Safety and tolerability of ND0801 will be based on adverse events reporting by the subjects during the study.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Attention Deficit and Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>ND0801</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ND0801</intervention_name>
    <description>Confidential</description>
    <arm_group_label>ND0801</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients.

          -  Men and women 18-55 years of age.

          -  Primary DSM-IV diagnosis of adult ADHD confirmed by senior physician

          -  Capable and willing to provide informed consent

          -  Able to adhere to the treatment schedule, and withdrawal of ongoing pharmacotherapy
             for the treatment of ADHD prior to the beginning of the study treatment and during
             the study drug treatment.

          -  Subjects must be able to read, hear, write and speak the local language.

          -  Subject has signed a written informed consent to participate in the study.

        Exclusion Criteria:

          -  Unstable or significant medical disorder.

          -  Current (within 12 months of baseline) primary or secondary depression.

          -  History of substance abuse or dependence within the past 6 months

          -  Any psychotic disorder (lifetime), including schizoaffective disorder, or major
             depression with psychotic features

          -  Bipolar disorder

          -  Eating disorder

          -  Obsessive compulsive disorder

          -  Post-traumatic stress disorder

          -  Current generalized anxiety disorder

          -  Presence of a personality disorder

          -  Individuals with a significant other neurological disorder.

          -  Use of any investigational drug within 4 weeks of the randomization visit

          -  Known or suspected pregnancy

          -  Women who are breast-feeding

          -  Women of childbearing potential and not using a medically accepted form of
             contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rambam Hospital</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shalvata Mental Health Center (SMHC)</name>
      <address>
        <city>Hod Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 5, 2012</lastchanged_date>
  <firstreceived_date>August 1, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
